盐酸替罗非班治疗非ST段抬高急性冠状动脉综合征40例临床疗效观察

目的探讨盐酸替罗非班治疗非ST段抬高急性冠状动脉综合征40例临床疗效。方法选择我院非ST段抬高型急性冠状动脉综合征80例,随机分为观察组和对照组。对照组采用常规治疗,观察组在常规治疗基础上给予替罗非班治疗。观察两组患者治疗后36h和治疗后30d内主要不良心血管事件发生情况,记录治疗期间出血发生情况。结果观察组患者治疗后36h主要不良心血管事件发生率显著低于对照组,差异有统计学意义(P<0.05);观察组患者治疗后30d主要不良心血管事件发生率显著低于对照组,差异有统计学意义(P<0.05)。观察组出血发生率与对照组比较,差异无统计学意义(P>0.05)。结论替罗非班能够降低非ST段抬高急性冠状动脉综合征患者主要不良心血管事件发生率,疗效显著,值得借鉴。

Observe the Clinical Efficacy of the 40 Cases of Non-ST-segment Elevation Acute Coronary Syndrome Patients with Tirofiban Treatment with Hydrochloric Acid

Objective Explore the clinical curative effect of tirofiban hydrochloride in treatment of non ST segment elevation acute coronary syndrome.Methods Selection of non ST segment elevation acute coronary syndrome in 80 cases,were randomly divided into observation group and control group.The control group was treated with routine treatment;the observation group was given tirofiban on the base of the conventional treatment.Major adverse cardiovascular events after treatment for 36 hours and 30 days was recorded in two groups,bleeding incidence was recorded during treatment.Results The incidence of major adverse cardiac events after treatment for 36 hours and 30 days were lower than that in control group after treatment for 36 hours and 30 days,the difference was statistically significant（P0.05）;in observation group,the incidence of bleeding compared with the control group,the difference was not statistically significant（P0.05）.Conclusion Tirofiban can reduce the incidence of major adverse cardiac events in the patients with non ST segment elevation acute coronary syndrome,the clinical efficacy is significant.